Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
9.36
-0.62 (-6.21%)
Jun 3, 2026, 10:49 AM EDT - Market open
Fennec Pharmaceuticals Revenue
Fennec Pharmaceuticals had revenue of $15.11M in the quarter ending March 31, 2026, with 72.64% growth. This brings the company's revenue in the last twelve months to $51.00M, up 64.98% year-over-year. In the year 2025, Fennec Pharmaceuticals had annual revenue of $44.64M, down -6.09%.
Revenue (ttm)
$51.00M
Revenue Growth
+64.98%
P/S Ratio
6.57
Revenue / Employee
$1,457,114
Employees
35
Market Cap
325.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.64M | -2.90M | -6.09% |
| Dec 31, 2024 | 47.54M | 26.29M | 123.69% |
| Dec 31, 2023 | 21.25M | 19.72M | 1,284.50% |
| Dec 31, 2022 | 1.54M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| REGENXBIO | 87.82M |
| Enanta Pharmaceuticals | 69.21M |
| Invivyd | 55.87M |
| Prelude Therapeutics | 16.72M |
| Lyell Immunopharma | 31.00K |
FENC News
- 12 days ago - Fennec price target raised to $16 from $13 at H.C. Wainwright - TheFly
- 12 days ago - Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 14 days ago - Fennec Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 15 days ago - Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Fennec Pharmaceuticals Slides: Corporate presentation - Filings
- 20 days ago - Fennec Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 20 days ago - Fennec Pharmaceuticals Earnings release: Q1 2026 - Filings
- 20 days ago - Fennec Pharmaceuticals Quarterly report: Q1 2026 - Filings